-
1
-
-
54149084585
-
Multiple sclerosis
-
Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
-
(2008)
Lancet
, vol.372
, pp. 1502-1517
-
-
Compston, A.1
Coles, A.2
-
2
-
-
84867916552
-
Development of oral agent in the treatment of multiple sclerosis: How the first available oral therapy, fingolimod will change therapeutic paradigm approach
-
Gasperini C, Ruggieri S. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther 2012;6:175-86
-
(2012)
Drug des Devel Ther
, vol.6
, pp. 175-186
-
-
Gasperini, C.1
Ruggieri, S.2
-
3
-
-
84874074752
-
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
-
Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;70:214-22
-
(2013)
J Neurol Neurosurg Psychiatry
, vol.70
, pp. 214-222
-
-
Scalfari, A.1
Neuhaus, A.2
Daumer, M.3
-
4
-
-
84896464812
-
-
National Multiple Sclerosis Society. The MS Disease - Modifying Medications. 2013. Available at [Last accessed 8 August 2011]
-
National Multiple Sclerosis Society. The MS Disease - Modifying Medications. 2013. Available at: www.nationalmssociety.org [Last accessed 8 August 2011]
-
-
-
-
5
-
-
84896461578
-
-
Electronic Medicines Compendium. Electronic Medicines Compendium. Available at [Last accessed August 2011]
-
Electronic Medicines Compendium. Electronic Medicines Compendium. Available at: http://emc.medicines.org.uk/ [Last accessed August 2011]
-
-
-
-
6
-
-
84866355653
-
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
-
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
-
(2012)
N Engl J Med
, vol.367
, pp. 1087-1097
-
-
Fox, R.J.1
Miller, D.H.2
Phillips, J.T.3
-
7
-
-
69149107165
-
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
-
W64
-
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64
-
(2009)
Ann Intern Med
, vol.151
, pp. 264-269
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
8
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
-
9
-
-
84896458149
-
-
NICE STA. Specification for manufacturer/sponsor submission of evidence October 2009. Available at [Last accessed August 2011]
-
NICE STA. Specification for manufacturer/sponsor submission of evidence October 2009. Available at: http://www.nice.org.uk/aboutnice/howwework/ devnicetech/singletechnologyappraisalsubmissiontemplates.jsp?domedia= 1&mid=4D9D8C83-19B9-E0B5-D4B0E148B3FE727F [Last accessed August 2011]
-
-
-
-
10
-
-
84896445080
-
-
IQWiG. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: General methods. Available at [Last accessed September 2011]
-
IQWiG. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: General methods. Available at: https://www.iqwig.de/download/ IQWiG- General-methods-V-3-0.pdf [Last accessed September 2011]
-
-
-
-
11
-
-
84896449642
-
-
The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions. Available at [Last accessed April 2013]
-
The Cochrane collaboration. Cochrane handbook for systematic reviews of interventions. Available at: http://handbook.cochrane.org/ [Last accessed April 2013]
-
-
-
-
12
-
-
0348012903
-
A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients
-
Milanese C, La ML, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-92
-
(2003)
J Neurol Neurosurg Psychiatry
, vol.74
, pp. 1689-1692
-
-
Milanese, C.1
La, M.L.2
Palumbo, R.3
-
13
-
-
80053302178
-
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: Are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination
-
Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord 2011;4:281-96
-
(2011)
Ther Adv Neurol Disord
, vol.4
, pp. 281-296
-
-
Limmroth, V.1
Putzki, N.2
Kachuck, N.J.3
-
14
-
-
33846118263
-
Rates and probabilities in economic modelling: Transformation, translation and appropriate application
-
Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6
-
(2007)
Pharmacoeconomics
, vol.25
, pp. 3-6
-
-
Fleurence, R.L.1
Hollenbeak, C.S.2
-
15
-
-
84866423965
-
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
-
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
-
(2012)
N Engl J Med
, vol.367
, pp. 1098-1107
-
-
Gold, R.1
Kappos, L.2
Arnold, D.L.3
-
16
-
-
17644436776
-
Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
-
Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-40
-
(1993)
J Interferon Res
, vol.13
, pp. 333-340
-
-
Knobler, R.L.1
Greenstein, J.I.2
Johnson, K.P.3
-
17
-
-
69949098534
-
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study
-
O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
-
(2009)
Lancet Neurol
, vol.8
, pp. 889-897
-
-
O'connor, P.1
Filippi, M.2
Arnason, B.3
-
18
-
-
19644372979
-
Effects of dose titration on tolerability and efficacy of interferon beta- 1b in people with multiple sclerosis
-
Wroe SJ. Effects of dose titration on tolerability and efficacy of interferon beta- 1b in people with multiple sclerosis. J Int Med Res 2005;33:309-18
-
(2005)
J Int Med Res
, vol.33
, pp. 309-318
-
-
Wroe, S.J.1
-
19
-
-
0029161628
-
Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
-
Sibley WA, Duquette P, Knobler RL, et al. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
-
(1995)
Neurology
, vol.45
, pp. 1277-1285
-
-
Sibley, W.A.1
Duquette, P.2
Knobler, R.L.3
-
20
-
-
80054944461
-
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
-
Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011;18:418-424
-
(2011)
Multiple Sclerosis
, vol.18
, pp. 418-424
-
-
Calabrese, M.1
Bernardi, V.2
Atzori, M.3
-
21
-
-
33645470729
-
Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis
-
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
-
(2006)
Acta Neurol Scand
, vol.113
, pp. 283-287
-
-
Etemadifar, M.1
Janghorbani, M.2
Shaygannejad, V.3
-
22
-
-
0023248694
-
A pilot trial of cop 1 in exacerbating- remitting multiple sclerosis
-
Bornstein MB, Miller A, Slagle S. A pilot trial of cop 1 in exacerbating- remitting multiple sclerosis. N Engl J Med 1987;317:408-14
-
(1987)
N Engl J Med
, vol.317
, pp. 408-414
-
-
Bornstein, M.B.1
Miller, A.2
Slagle, S.3
-
23
-
-
78650159514
-
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Results of a phase II randomised placebo-controlled multicentre trial
-
Kappos L, Calabresi P, Connor P, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Multiple Sclerosis 2010; 16:S33-4
-
(2010)
Multiple Sclerosis
, vol.16
-
-
Kappos, L.1
Calabresi, P.2
Connor, P.3
-
24
-
-
67649476210
-
Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study
-
Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
-
(2009)
Neurology
, vol.72
, pp. 1976-1983
-
-
Cadavid, D.1
Wolansky, L.J.2
Skurnick, J.3
-
25
-
-
84880843972
-
Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing remitting multiple sclerosis
-
10-13 October 2012. Lyon, France, P491
-
Calabresi PA, Goodin D, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing remitting multiple sclerosis. 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 10-13 October 2012. Lyon, France, P491
-
28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)
-
-
Calabresi, P.A.1
Goodin, D.2
Jeffery, D.3
-
26
-
-
33644584352
-
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
-
Polman CH, Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910
-
(2006)
N Engl J Med
, vol.354
, pp. 899-910
-
-
Polman, C.H.1
Connor, P.W.2
Havrdova, E.3
-
27
-
-
76149093586
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
-
Kappos L, Radue EW, Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362: 387-401
-
(2010)
N Engl J Med
, vol.362
, pp. 387-401
-
-
Kappos, L.1
Radue, E.W.2
Connor, P.3
-
28
-
-
76149140914
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
-
(2010)
N Engl J Med
, vol.362
, pp. 402-415
-
-
Cohen, J.A.1
Barkhof, F.2
Comi, G.3
-
29
-
-
80053533877
-
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
-
O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365: 1293-303
-
(2011)
N Engl J Med
, vol.365
, pp. 1293-1303
-
-
O'connor, P.1
Wolinsky, J.S.2
Confavreux, C.3
-
31
-
-
77955044842
-
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis
-
De Stefano N, Curtin F, Stubinski B, et al. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. Multiple Sclerosis 2010;16:888-92
-
(2010)
Multiple Sclerosis
, vol.16
, pp. 888-892
-
-
De Stefano, N.1
Curtin, F.2
Stubinski, B.3
-
33
-
-
84875657789
-
Recent advances in treating multiple sclerosis: Efficacy, risks and place in therapy
-
Jeffery DR. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther Adv Chronic Dis 2013;4:45-51
-
(2013)
Ther Adv Chronic Dis
, vol.4
, pp. 45-51
-
-
Jeffery, D.R.1
-
34
-
-
84896455775
-
Safety profile of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: Long-term interim results from the ENDORSE extension study
-
2-5 October 2013. Copenhagen, Denmark
-
Phillips JT, Fox RJ, Selmaj K, et al. Safety profile of BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2-5 October 2013. Copenhagen, Denmark
-
29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
-
-
Phillips, J.T.1
Fox, R.J.2
Selmaj, K.3
-
35
-
-
82455215753
-
Heterogeneity in multiple sclerosis: Scratching the surface of a complex disease
-
Disanto G, Berlanga AJ, Handel AE, et al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis 2010; 2011:932351
-
(2010)
Autoimmune Dis
, vol.2011
, pp. 932351
-
-
Disanto, G.1
Berlanga, A.J.2
Handel, A.E.3
-
36
-
-
84896472125
-
-
The American Academy of Neurology's 64th AAN Annual Meeting. 21-28 April 2012. New Orleans, LA, SO1.003
-
Fox R, Miller D, Phillips JT, et al. Clinical efficacy of BG-12 in relapsing- remitting multiple sclerosis (RRMS): data from the phase 3 CONFIRM study. The American Academy of Neurology's 64th AAN Annual Meeting. 21-28 April 2012. New Orleans, LA, SO1.003
-
Clinical Efficacy of BG-12 in Relapsing- Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study
-
-
Fox, R.1
Miller, D.2
Phillips, J.T.3
-
37
-
-
0345601517
-
Randomised double-blind placebocontrolled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis
-
Ebers GC, Rice G, Lesaux J, et al. Randomised double-blind placebocontrolled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
-
(1998)
Lancet
, vol.352
, pp. 1498-1504
-
-
Ebers, G.C.1
Rice, G.2
Lesaux, J.3
-
38
-
-
36849035929
-
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon (beta)-1a for relapsing multiple sclerosis
-
Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon (beta)-1a for relapsing multiple sclerosis. Clin Therapeut 2007;29:2031-48
-
(2007)
Clin Therapeut
, vol.29
, pp. 2031-2048
-
-
Schwid, S.R.1
Panitch, H.S.2
-
39
-
-
51449101000
-
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
-
Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
-
(2008)
Lancet Neurol
, vol.7
, pp. 903-914
-
-
Mikol, D.D.1
Barkhof, F.2
Chang, P.3
-
40
-
-
0029082566
-
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double- blind, placebo-controlled trial
-
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 1995;45:1268-76
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
-
41
-
-
0035091667
-
European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
-
Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7
-
(2001)
Ann Neurol
, vol.49
, pp. 290-297
-
-
Comi, G.1
Filippi, M.2
Wolinsky, J.S.3
-
42
-
-
0008678962
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
-
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-94
-
(1996)
Ann Neurol
, vol.39
, pp. 285-294
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
-
43
-
-
0037181634
-
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
-
Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359: 1453-60
-
(2002)
Lancet
, vol.359
, pp. 1453-1460
-
-
Durelli, L.1
Verdun, E.2
Barbero, P.3
-
44
-
-
84866021501
-
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
-
Saida T, Kikuchi S, Itoyama Y, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Multiple Sclerosis 2012;18:1269-77
-
(2012)
Multiple Sclerosis
, vol.18
, pp. 1269-1277
-
-
Saida, T.1
Kikuchi, S.2
Itoyama, Y.3
-
45
-
-
33645799680
-
A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
-
O'Connor P, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900
-
(2006)
Neurology
, vol.66
, pp. 894-900
-
-
O'connor, P.1
Li, D.2
Freedman, M.S.3
|